Clinical Trial Update: S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating S-1 in combination with bevacizumab for colorectal cancer that is recurrent or unresectable.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Osaka Medical College | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN